Senesco Makes Progress

As we have suggested Senesco technologies is now “in the clinic” with its first cancer therapy SNS01-T. The tests at the Mayo Clinic are underway as I write this Morning Note. This test is a Phase 1B /2A safety test of SNT’s multiple myeloma therapy but we will have some indication of the success of the therapy as the dosage is increased.

The company also announced today that it had run tests on two other cancers human mantle cell and diffuse large B-cell lymphomas in the mouse model. Les Browne Senesco’s CEO said, “The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models.”

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]